Baltruškevičienė E, Mickys U, Žvirblis T, Stulpinas R, Pipirienė Želvienė T, Aleknavičius E. Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. AML [Internet]. 2016 Apr. 7 [cited 2024 Jul. 17];23(1):24-3. Available from: https://www.journals.vu.lt/AML/article/view/21456